CDAK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (5 Apr 2024 @ 04:00):

Stats
今日成交量	14.21M
平均成交量	0.00
市值	2.83M
EPS	$0 ( 2023-11-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0210 (105.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-30	Howze Yalonda	Sell	1 628	Common Stock
2023-03-29	Sathyanarayanan Sriram	Sell	11 762	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	7 432	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	1 932	Common Stock
2023-03-28	Bain Linda	Sell	13 412	Common Stock

INSIDER POWER
92.91
Last 100 transactions
Buy: 14 044 661 \| Sell: 316 076

音量相关性

長: -0.25 (neutral)

短: 0.79 (moderate)

Signal:(35.08) Neutral

Codiak BioSciences, Inc. 相关性

10 最正相关
DTEA	0.934
PAYO	0.888
NAII	0.886
MKTX	0.884
NLSP	0.883
PMTS	0.883
OBNK	0.88
PRAA	0.879
THMA	0.877
VEDU	0.876

10 最负相关
RMRM	-0.947
CVLT	-0.945
EVLV	-0.941
APYX	-0.937
FLXN	-0.937
CELH	-0.935
APLD	-0.929
PRSR	-0.927
QTRX	-0.926
CNCE	-0.925

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Codiak BioSciences, Inc. 相关性 - 货币/商品

-0.35
( neutral )

-0.58
( weak negative )

-0.76
( moderate negative )

0.43
( neutral )

Codiak BioSciences, Inc. 财务报表

Annual	2021
营收:	$22.94M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.664

FY	2021
营收:	$22.94M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.664

FY	2020
营收:	$2.92M
毛利润:	$2 915.00 (0.10 %)
EPS:	$-16.18

FY	2019
营收:	$388 000
毛利润:	$0.00 (0.00 %)
EPS:	$-5.96

Financial Reports:

No articles found.

Codiak BioSciences, Inc.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.